CJC Open最新文献

{"title":"Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial","authors":"Ayodele Odutayo MD, DPhil ,&nbsp;Bernard Zinman MD ,&nbsp;Christoph Wanner MD ,&nbsp;Isabella Zwiener PhD ,&nbsp;Søren S. Lund MD ,&nbsp;Stefan Hantel PhD ,&nbsp;David Fitchett MD ,&nbsp;Jacob A. Udell MD ,&nbsp;EMPA-REG OUTCOME Trial Investigators","doi":"10.1016/j.cjco.2024.01.013","DOIUrl":"10.1016/j.cjco.2024.01.013","url":null,"abstract":"<div><h3>Background</h3><p>In patients with type 2 diabetes mellitus (T2DM), a history of an ischemic event is associated with increased risk for cardiovascular (CV) disease. Whether patients with T2DM and a recent atherothrombotic diagnosis benefit from early intervention with a sodium-glucose co-transporter 2 inhibitor is unknown.</p></div><div><h3>Methods</h3><p>This study is a secondary analysis of the <strong>Empa</strong>gliflozin Cardiovascular <strong>Outcome</strong> Event Trial in Type 2 Diabetes Mellitus Patients–<strong>R</strong>emoving <strong>E</strong>xcess <strong>G</strong>lucose (EMPA-REG OUTCOME), which compared empagliflozin to placebo in adults with T2DM and atherosclerotic CV disease (ASCVD). Participants were categorized based on the time since their last qualifying ASCVD diagnosis (≤ 1 year vs &gt; 1 year). Qualifying ASCVD diagnoses included ischemic or hemorrhagic stroke, myocardial infarction, coronary artery disease, and peripheral artery disease. The primary outcome was a composite of CV death, nonfatal myocardial infarction, or nonfatal stroke.</p></div><div><h3>Results</h3><p>A total of 6796 participants (n = 4547 empagliflozin, n = 2249 placebo) were included. Median time since the last qualifying ASCVD diagnosis was 3.8 years (quartile 1-quartile 3: 1.5-7.6), and most qualifying diagnoses occurred &gt; 1 year before randomization (≤ 1 year, n = 1214; &gt; 1 year, n = 5582). Empagliflozin reduced the incidence of the primary outcome irrespective of the time since the last qualifying ASCVD diagnosis (≤ 1 year: hazard ratio 0.82, 95% confidence interval: 0.57-1.16; vs &gt; 1 year: hazard ratio 0.85, 95% confidence interval: 0.72-1.00; <em>P</em> for interaction = 0.84). Results were similar for the composite of CV death or hospitalization for heart failure.</p></div><div><h3>Conclusions</h3><p>Empagliflozin improved CV outcomes in participants with T2DM, irrespective of the time since the last qualifying ASCVD diagnosis at randomization. Prospective trials are necessary to investigate the use of sodium-glucose co-transporter 2 inhibitors at the time of an acute ASCVD event.</p></div><div><h3>Trial Registration</h3><p>EMPA-REG OUTCOME (<span>Clinicaltrials.gov</span><svg><path></path></svg> identifier: <span>NCT01131676</span><svg><path></path></svg>).</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"6 7","pages":"Pages 868-875"},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24000490/pdfft?md5=2e2314ae9ff76d3b5a18bafe9ae541a3&pid=1-s2.0-S2589790X24000490-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139877268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of an Accelerated Diagnostic Protocol Using Conventional Troponin I for Patients With Cardiac Chest Pain in the Emergency Department","authors":"Jesse Hill MD, MSc ,&nbsp;Esther H. Yang BSc, MSc ,&nbsp;Dennis Lefebvre MD, PhD ,&nbsp;Shandra Doran MD, PhD ,&nbsp;Sean van Diepen MD, FRCPC ,&nbsp;Joshua E. Raizman PhD ,&nbsp;Albert K.Y. Tsui PhD ,&nbsp;Brian H. Rowe MD, MSc","doi":"10.1016/j.cjco.2024.03.008","DOIUrl":"https://doi.org/10.1016/j.cjco.2024.03.008","url":null,"abstract":"<div><h3>Background</h3><p>This study strove to assess the impact of the implementation of an accelerated diagnostic protocol (ADP), using shortened serial-testing intervals and a conventional troponin I (c-TnI) test, on emergency department (ED) length of stay (LOS).</p></div><div><h3>Methods</h3><p>This retrospective cohort study included adults (aged ≥ 18 years) presenting to a Canadian ED with a primary complaint of cardiac chest pain between January 14, 2017 and January 15, 2019. For non-high-risk patients, the troponin delta timing decreased from 6 hours to 3 hours, and a different conventional troponin I level cut-point was implemented on January 15, 2018. The primary outcome was ED LOS. Secondary outcomes included disposition status, consultation proportions, and major adverse cardiac events within 30 days.</p></div><div><h3>Results</h3><p>A total of 3133 patient interactions were included. Although the overall decrease in median ED LOS was not significant (<em>P</em> = 0.074), a significant reduction occurred in ED LOS (-33 minutes; 95% confidence interval: -53.6 to -12.4 minutes) among patients who were discharged in the post-ADP group. Consultations were unchanged between groups (36.1% before vs 33.8% after; <em>P</em> = 0.17). The major adverse cardiac events outcomes were unchanged across cohorts (15.9% vs 15.3%; <em>P</em> = 0.62).</p></div><div><h3>Conclusions</h3><p>The implementation of an ADP, with a conventional troponin I test, for cardiac chest pain in a Canadian ED was not associated with a significant reduction of LOS for all patients; however, a significant reduction occurred for patients who were discharged, and the strategy appears safe.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"6 7","pages":"Pages 915-924"},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24001409/pdfft?md5=c44c3b996ffcc2926e5ce9404a03bec2&pid=1-s2.0-S2589790X24001409-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141543038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Out-of-Hospital Cardiac Arrest From Malignant Early Repolarization Syndrome","authors":"Jung-In Choi MD, MPH ,&nbsp;Sammy Chan MD, FRCPC ,&nbsp;Andrew Krahn MD, FCCS","doi":"10.1016/j.cjco.2024.04.007","DOIUrl":"https://doi.org/10.1016/j.cjco.2024.04.007","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"6 7","pages":"Pages 905-907"},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X2400177X/pdfft?md5=65498b8d88abbcfac9a460233fd8082d&pid=1-s2.0-S2589790X2400177X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141543039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Prevalence of Atrial Fibrillation Found in the Capital of Greenland When Using Continuous Electrocardiogram Monitoring: A Cross-Sectional Study","authors":"Nadja Albertsen MD, MSA ,&nbsp;Mads Mose Jensen MD ,&nbsp;Kunuk Lauge Koch Hansen ,&nbsp;Michael Lynge Pedersen MD, MedScD ,&nbsp;Stig Andersen MD, PhD ,&nbsp;Christina Brock MSc, PhD ,&nbsp;Sam Riahi MD, PhD","doi":"10.1016/j.cjco.2024.03.011","DOIUrl":"10.1016/j.cjco.2024.03.011","url":null,"abstract":"<div><h3>Background</h3><p>Atrial fibrillation (AF) increases the risk of conditions such as ischemic stroke, dementia, and heart failure, and early detection is crucial. In Greenland, ischemic strokes are common, and the prevalences of AF risk factors are increasing. Studies based on 30-second electrocardiograms (ECGs) and diagnosis codes so far have indicated either a low prevalence of AF or a prevalence comparable to that in other Western countries, such as Denmark. However, using short, single-point ECGs may underestimate the true prevalence, as especially paroxysmal AF can be missed. With this study, we aim to estimate the prevalence of AF using 3-5–day continuous Holter recordings among people in Nuuk, the capital of Greenland.</p></div><div><h3>Methods</h3><p>In this cross-sectional study, we estimated the prevalence of AF among the population aged ≥ 50 years in Greenland’s capital, Nuuk. We used an ePatch to record continuous ECGs for 3-5 days, and questionnaires to assess demographic data, comorbidities, medication, symptoms, and risk factors for AF.</p></div><div><h3>Results</h3><p>Of 226 participants (62% women), 21 (33% women) had either self-reported AF, AF on the recording, or both, equivalent to a prevalence of 9.3% (confidence interval [CI] 5.8-13.9). The age-stratified prevalence was 7.2% (CI 2.7-15.1) among those aged 50-59 years; 8.8% (CI 4.1-16.1) among those aged 60-69 years; and 18.2% (CI 7.0-35.5) among those aged ≥ 70 years.</p></div><div><h3>Conclusions</h3><p>This study provides a novel insight into AF prevalence in Nuuk, emphasizing the potential underestimation in previous studies. Continuous ECG monitoring revealed a higher prevalence, especially among the younger age groups, urging a reevaluation of diagnostic practices in this unique population.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"6 7","pages":"Pages 884-892"},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24001434/pdfft?md5=67992e059b63f1af83a0d2a5a29b8b15&pid=1-s2.0-S2589790X24001434-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140402309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Patient Viewpoints to Optimize Implementation of a Biological Therapy for Atrial Fibrillation Prevention","authors":"Chloé Smith MD ,&nbsp;Manoj M. Lalu MD, PhD ,&nbsp;Darryl R. Davis MD","doi":"10.1016/j.cjco.2024.04.003","DOIUrl":"10.1016/j.cjco.2024.04.003","url":null,"abstract":"<div><h3>Background</h3><p>Embracing patient viewpoints can enhance the translation of novel therapeutics to clinical settings. This study evaluated the acceptability of using extracellular vesicles (EVs) as a biological therapy for preventing postoperative atrial fibrillation (AF), through engagement with patients, providing insights into their attitudes and information needs.</p></div><div><h3>Methods</h3><p>Patients participated in prerecorded presentations, virtual focus groups, and surveys to assess their perspectives on EV therapy and determine the factors influencing their acceptance of the intervention.</p></div><div><h3>Results</h3><p>Participants with postoperative AF experienced prolonged intensive care unit and hospital stays, compared to those of patients with normal heart rhythm. Prior to the presentation, a number of participants were unfamiliar with postoperative AF and biological therapies. However, postpresentation and post–focus group activities resulted in enhanced understanding of the research, with high levels of comprehension reported by all participants. The level of acceptance of EV therapy tended to increase, with a majority expressing willingness to participate in clinical trials and accept the therapy. The focus groups identified and addressed common questions regarding the potential risks and side effects of EVs, their source, dosing, utility for patients with preexisting AF, and the risk of human immunodeficiency virus (HIV) contraction or allergic reactions.</p></div><div><h3>Conclusions</h3><p>The study highlights the importance of providing education, involving the patient's circle of care, and addressing patient concerns, to promote acceptance of therapies such as EV therapy for postoperative AF.</p></div><div><h3>Clinical Trial Registration</h3><p><span>NCT05032495</span><svg><path></path></svg>.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"6 7","pages":"Pages 893-900"},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24001720/pdfft?md5=0011c792af7514aaa0ff933653ee7f38&pid=1-s2.0-S2589790X24001720-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140769249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinguishing Primary Prevention From Secondary Prevention Implantable Cardioverter Defibrillators Using Administrative Health and Cardiac Device Registry Data","authors":"Isaac Robinson ,&nbsp;Daniel Daly-Grafstein MSc ,&nbsp;Mayesha Khan MA ,&nbsp;Andrew D. Krahn MD ,&nbsp;Nathaniel M. Hawkins MD ,&nbsp;Jeffrey R. Brubacher MD ,&nbsp;John A. Staples MD, MPH","doi":"10.1016/j.cjco.2024.02.003","DOIUrl":"10.1016/j.cjco.2024.02.003","url":null,"abstract":"<div><h3>Background</h3><p>Administrative health data and cardiac device registries can be used to empirically evaluate outcomes and costs after implantable cardioverter defibrillator (ICD) implantation. These datasets often have incomplete information on the indication for implantation (primary vs secondary prevention of sudden cardiac death).</p></div><div><h3>Methods</h3><p>We used 16 years of population-based cardiac device registry and administrative health data from British Columbia, Canada, to derive and internally validate statistical models that predict the likely indication for ICD implantation. We used chart review data as the reference standard for ICD indication in the Cardiac Device Registry database (CDR; 2004-2012 [Cardiac Services BC]) and nonmissing indication as the reference standard in the Heart Information System registry database (HEARTis; 2013-2019 [Cardiac Services BC]). We created 3 logistic regression prediction models in each database: one using only registry data, one using only administrative data, and one using both registry and administrative data. We assessed the predictive performance of each model using standard metrics after optimism correction with 200 bootstrap resamples.</p></div><div><h3>Results</h3><p>Models that used registry data alone demonstrated excellent predictive performance (sensitivity ≥ 89%; specificity ≥ 87%). Models that used only administrative data performed well (sensitivity ≥ 84%; specificity ≥ 70%). Models that used both registry and administrative data showed modest gains over those that used registry data alone (sensitivity ≥ 90%; specificity ≥ 89%).</p></div><div><h3>Conclusions</h3><p>Administrative health data and cardiac device registry data can distinguish secondary prevention ICDs from primary prevention ICDs with acceptable sensitivity and specificity. Imputation of missing ICD indication might make these data resources more useful for research and health system monitoring.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"6 7","pages":"Pages 876-883"},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24001318/pdfft?md5=b6f80249de14a72de0fb35d00c943801&pid=1-s2.0-S2589790X24001318-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140271386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescription Trends of Thiazide Diuretics in a Canadian Primary Care Population From 2015 to 2021","authors":"Catherine Ji MD, MSc ,&nbsp;Jemisha Apajee MPhil ,&nbsp;Ellen Stephenson PhD ,&nbsp;Karen Tu MD, Msc","doi":"10.1016/j.cjco.2024.03.001","DOIUrl":"10.1016/j.cjco.2024.03.001","url":null,"abstract":"<div><h3>Background</h3><p>Hypertension Canada 2017 guidelines favoured the use of thiazide (TZ)-like diuretics, such as CLTD (chlorthalidone) and indapamide (IND) over hydrochlorothiazide (HCTZ). Health Canada warned in 2019 that HCTZ may be associated with increased risk of skin cancer. Our study looked at the changes in TZ prescriptions from 2015 to 2021 in Ontario, Canada.</p></div><div><h3>Methods</h3><p>A retrospective cohort study was conducted of adults with hypertension, using electronic medical record data from the University of Toronto Practice-Based Research Network database covering mostly the Greater Toronto area. Outcomes included the proportion of patients who received a prescription of HCTZ, CLTD, or IND each month. Interrupted time-series analysis was used to evaluate the change in outcomes after publication of the 2017 guidelines and 2019 safety warning. Prescription trends were stratified by prescribing physicians’ sex and year of medical school graduation.</p></div><div><h3>Results</h3><p>A total of 100,428 patients with hypertension were included in the cohort, with 31,700 patients who received at least one TZ prescription from 343 family physicians. We found a declining trend in HCTZ prescriptions over time, accompanied by an increase in IND and CLTD prescriptions, with statistically significant but transient changes in prescription rates after publication of the 2017 guidelines and the 2019 safety warning for all 3 medications. Female physician and early-career physician prescription rates changed faster than that of their counterparts immediately after the Health Canada safety warning was issued.</p></div><div><h3>Conclusions</h3><p>TZ diuretic prescription patterns have changed in recent years, but Hypertension Canada’s 2017 guidelines and the 2019 Health Canada safety warning did not have a sustained significant impact on the change in prescription rates of HCTZ, IND, and CLTD.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"6 6","pages":"Pages 790-797"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X2400132X/pdfft?md5=b3c1d6094bbfb1566b2cd0c9ae03e244&pid=1-s2.0-S2589790X2400132X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140281935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphopenia in the Adult Population With Fontan Physiology: A Potential New Marker for Disease Assessment","authors":"Anna L. Scandinaro MD ,&nbsp;Michael D. McCann MD, MBA ,&nbsp;Anisa Chaudhry MD ,&nbsp;Allen Kunselman MA ,&nbsp;Elisa A. Bradley MD ,&nbsp;William R. Davidson Jr. MD","doi":"10.1016/j.cjco.2024.01.012","DOIUrl":"10.1016/j.cjco.2024.01.012","url":null,"abstract":"<div><h3>Background</h3><p>Patients with complex congenital heart disease and Fontan palliation frequently develop extracardiac disease, including hematologic abnormalities, such as lymphopenia. However, the clinical implications of this finding are poorly understood and are therefore the topic of this investigation.</p></div><div><h3>Methods</h3><p>Patients with Fontan physiology in our centre (1999-2018) were evaluated for the presence and impact of lymphopenia. The cohort was divided into a group with lymphopenia (L) (2 consecutive absolute lymphocyte counts ≤ 1∗10³ K/ μL) and a group who had never had lymphopenia (NL). Clinical characteristics and hospital admissions (762 patient-years) were evaluated.</p></div><div><h3>Results</h3><p>In 62 adult patients with Fontan physiology (aged 34 ± 9 years; 32 women [52%]), the patients who developed lymphopenia earliest did so 8 years after Fontan completion, with up to 60% of patients developing lymphopenia by 30 years. Lymphopenia was found to be associated with portal hypertension (varices, ascites, splenomegaly, and thrombocytopenia [VAST] score)—NL: 0 (0-2) vs L: 2 (0-4), <em>P</em> &lt; 0.0001). A total of 76 heart failure and 81 arrhythmia-associated admissions occurred per 1000 patient-years. At 40 years post-Fontan, the probability of a heart failure admission was higher in the L group (L: 51 [86%] vs NL: 8 [14%], <em>P</em> &lt; 0.01).</p></div><div><h3>Conclusions</h3><p>Adult patients with Fontan physiology and lymphopenia demonstrated portal hypertension and lymphatic dysfunction more commonly, perhaps suggesting that this may be a marker of Fontan congestion and early Fontan failure. Further investigation into the relationship between lymphopenia, clinical outcomes, and Fontan function is needed.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"6 6","pages":"Pages 773-780"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24000489/pdfft?md5=3abb08f99b6f56577e12ea65ab241cb6&pid=1-s2.0-S2589790X24000489-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139891783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progression of Left Ventricular Aneurysm to Pseudoaneurysm on Serial Imaging","authors":"Yoshito Kadoya MD, PhD ,&nbsp;Alexander Dick MD ,&nbsp;Hassan Mir MD ,&nbsp;Luc Beauchesne MD ,&nbsp;D. Ian Paterson MD","doi":"10.1016/j.cjco.2024.04.002","DOIUrl":"10.1016/j.cjco.2024.04.002","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"6 6","pages":"Pages 843-845"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24001719/pdfft?md5=0caf82efc3caa388feb43fb4da0299f6&pid=1-s2.0-S2589790X24001719-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140792011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal Assessment of Immunosuppressive Therapy in a Patient With Chronic Active Myocarditis 3 Months Following COVID-19 Infection","authors":"Yuta Kobayashi MD, PhD ,&nbsp;Takeshi Hamaya MD ,&nbsp;Toshiyuki Nagai MD, PhD ,&nbsp;Yuki Mori MD ,&nbsp;Takuma Sato MD, PhD ,&nbsp;Satonori Tsuneta MD, PhD ,&nbsp;Kento Wakabayashi MD ,&nbsp;Kohsuke Kudo MD, PhD ,&nbsp;Yoshihiro Matsuno MD, PhD ,&nbsp;Toshihisa Anzai MD, PhD","doi":"10.1016/j.cjco.2024.03.010","DOIUrl":"10.1016/j.cjco.2024.03.010","url":null,"abstract":"","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"6 6","pages":"Pages 826-829"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24001422/pdfft?md5=1a9c38929a66d517bdd2b534f9a403a3&pid=1-s2.0-S2589790X24001422-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140402042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}